Allurion outlines path to FDA submission and expects revenue ramp as B2B2C strategy expands in 2025

Stock Information for Allurion Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Allurion Technologies Inc.

Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS
Allurion to Present at Jefferies Global Healthcare Conference
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.